Information Provided By: 
Fly News Breaks for August 9, 2019
AIMT
Aug 9, 2019 | 08:22 EDT
RBC Capital analyst Kennen MacKay lowered his price target on Aimmune to $50 after its Q2 earnings miss, also reducing his launch expectations for AR101 based on the analysis of the "recent comparable drug launches into indications with a similar unmet need." The analyst still keeps his Outperform rating on the stock and sees AR101 as well positioned to "disrupt and build the peanut allergy desensitization market".
News For AIMT From the Last 2 Days
There are no results for your query AIMT
